Distinguished in Neuroendocrine Tumor

Vicente R. Alonso

Zaragoza, AR, ES 
Distinguished in Neuroendocrine Tumor
Zaragoza, AR, ES 
OverviewLocationsClinical Research

Overview

Vicente Alonso practices in Zaragoza, Spain. Mr. Alonso is rated as a Distinguished expert by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Colorectal Cancer, Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, and Pancreatic Cancer.

His clinical research consists of co-authoring 55 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 18 articles and participated in 2 clinical trials in the study of Neuroendocrine Tumor.

Gender
Male

Locations

Zaragoza, AR, Spain
Other Locations
Plasencia De Jalon, AR 10600, Spain
H. Santa Creu i Sant Pau
Barcelona, CT, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Trial of Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).
Phase II Trial of Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).
Enrollment Status: Unknown
Publish Date: February 24, 2023
Intervention Type: Drug
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
Enrollment Status: Terminated
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 3
Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer
Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer
Enrollment Status: Unknown
Publish Date: March 16, 2022
Intervention Type: Biological, Drug
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
Enrollment Status: Unknown
Publish Date: February 02, 2021
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Enrollment Status: Completed
Publish Date: March 24, 2020
An Open Label, Phase II Study Assessing Potential Predictive Tumor Markers in Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor Treated With FOLFOX Plus Panitumumab as First-line Therapy
An Open Label, Phase II Study Assessing Potential Predictive Tumor Markers in Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor Treated With FOLFOX Plus Panitumumab as First-line Therapy
Enrollment Status: Completed
Publish Date: May 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

55 Total Publications

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A multi-cohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A multi-cohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Alonso's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile